N/A
N=1,584
Volatile Anesthetic Choice and Duration of Hospitalization: A Quality Improvement and Cost-control Project
Duration of Hospitalization
Bottom Line
View on ClinicalTrials.gov: NCT01379664 ↗Enrolled (actual)
1,584
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Hospital Length of Stay — 4.9; 4.4 Days — p=0.24
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Isoflurane (Drug); Sevoflurane (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- The Cleveland Clinic
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hospital Length of Stay |
4.9; 4.4 | 0.24 |
| SECONDARY Time-weighted Average Verbal Rating Pain Score |
3.6; 3.6 | 0.87 |
| SECONDARY Total Intraoperative Opioid Consumption |
32; 33 | 0.74 |
Summary
Preliminary retrospective data suggest that the relatively soluble but inexpensive volatile anesthesia isoflurane prolongs the duration of hospitalization compared to the less soluble but more expensive anesthetic sevoflurane. Even a small reduction in the duration of hospitalization would easily compensate for the modest additional cost of sevoflurane. The investigators therefore propose to test the primary hypothesis that duration of hospitalization is longer with isoflurane than sevoflurane.
The investigators will also test the secondary hypotheses that: 1) pain scores are greater in patients recovering from isoflurane than sevoflurane anesthesia; and, 2) opioid consumption is greater after isoflurane than sevoflurane anesthesia. All statistical analyses will be adjusted for age, gender, race, baseline risk, 9 and procedure.
Eligibility Criteria
Inclusion Criteria
- Must have surgery in G operating room suite
Data sourced from ClinicalTrials.gov (NCT01379664). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.